Explaining racial and ethnic differences in children's use of stimulant medications

Medical Care

Volumn 45, Issue 11, 2007, Pages 1068-1075

  Hudson, Julie L ^a   Miller, G Edward ^a   Kirby, James B ^a  

^a AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

Author keywords

ADHD; Child health; Psychotherapeutic drugs; Stimulant use

Indexed keywords

CENTRAL STIMULANT AGENT;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; DRUG UTILIZATION; ETHNOLOGY; FEMALE; HEALTH INSURANCE; HUMAN; INSURANCE; MALE; MENTAL HEALTH; PRESCHOOL CHILD; SOCIOECONOMICS;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; DRUG UTILIZATION; FEMALE; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; MALE; MENTAL HEALTH; SOCIOECONOMIC FACTORS;

EID: 37349101216     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e31806728fa     Document Type: Article

References (36)

1. Rowland A, Lesesne C, Abramowitz A. The epidemiology of attention-deficit/ hyperactivity disorder (ADHD): a public health view. Ment Retard Dev Disabil Res Rev. 2002;8:162-170.
2. Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108:1033-1044.
3. US Department of Justice, Drug Enforcement Administration. Methylphenidate (A Background Paper). Washington, DC: Drug and Chemical Evaluation Section Office of Diversion Control; October 1995.
4. Zuvekas S, Vitiello B, Norquist G. Recent trends in stimulant medication use among US children. Am J Psychiatry. 2006;163:579-585.
5. Zito J, Safer D, dosReis S, et al. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2000;283:1025-1030.
6. Olfson M, Marcus SC, Weissman MM, et al. National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry. 2002;41:514-521.
7. The Associated Press. Feds Recommend Warnings on ADHD Drugs. New York, NY: The Associated Press; February 10, 2006.
8. Shankar V. Washington Post Staff Writer. Warning urged for ADHD drugs. Panel cites risks, fears of overuse. Washington Post, February 10, 2006:A01.
9. Raghavan R, Zima B, Anderson R, et al. Psychotropic medication use in a national probability sample of children in the child welfare system. J Child Adolesc Psychopharmacol. 2005;15:97-106.
10. Rowland AS, Umbach DM, Stallone L, et al. Prevalence of medication treatment for attention deficit-hyperactivity disorder among elementary school children in Johnston County, North Carolina. Am J Public Health. 2002;92:231-234.
11. Zito JM, Safer DJ, Zuckerman IH, et al. Effect of Medicaid eligibility category on racial disparities in the use of psychotropic medications among youths. Psychiatr Serv. 2005;56:157-163.
12. Zito JM, Safer DJ, dosReis S, et al. Racial disparity in psychotropic medications prescribed for youths with Medicaid insurance in Maryland. J Am Acad Child Adolesc Psychiatry. 1998;37:179-184.
13. Stevens J, Harman J, Kelleher K. Ethnic and regional differences in primary care visits for attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2004;25:318-325.
14. Stevens J, Harman J, Kelleher K. Race/ethnicity and insurance status as factors associated with ADHD treatment patterns. J Child Adolesc Psychopharmacol. 2005;15:88-96.
15. Cox E, Motheral B, Henderson R, et al. Geographic variation in the prevalence of stimulant medication use among children 5 to 14 years old: results from a commercially insured US sample. Pediatrics. 2003;111:237-243.
16. Jensen PS, Kettle L, Roper M, et al. Are stimulants overprescribed? Treatment of ADHD in four U.S. communities. J Am Acad Psychiatry. 1999;38:797-804.
17. Brown E Jr. Children's Usual Source of Care: United States, 2002. Rockville, MD: Agency for Healthcare Research and Quality; 2005. Statistical Brief No. 78. Available at: http://www.meps.ahrq.gov/papers/st78/stat78.pdf.
18. Chen A, Chang R. Factors associated with prescription drug expenditures among children: an analysis of the medical expenditure panel survey. Pediatrics. 2002;109:728-732.
19. Guevara JP, Mandell DS, Rostain AL, et al. Disparities in the reporting and treatment of health conditions in children: an analysis of the medical expenditure panel survey. Health Serv Res. 2006;41:532-549.
20. Miller GE, Hudson JL. Children and antibiotics: analysis of reduced use, 1996-2001. Med Care. 2006;44(5 Suppl):I36-I44.
21. Miller GE, Carroll WA. Trends in Children's Antibiotic Use, 1996 to 2001. Rockville, MD: Agency for Healthcare Research and Quality; 2005. MEPS Research Findings No. 23. AHRQ Pub. No. 05-0020.
22. Oaxaca RL. Male-female wage differentials in urban labor markets. Int Econ Rev. 1973;14:693-709.
23. Blinder A. Wage discrimination - reduced form and structural estimates. J Hum Resour. 1973;8:436-455.
24. Kirby JB, Taliaferro G, Zuvekas S. Explaining racial and ethnic disparities in health care. Med Care. 2006;44(5 Suppl):I64-I72.
25. Oaxaca RL, Michael RR. Identification in detailed wage decompositions. Rev Econ Stat. 1999;81:154-157.
26. Cohen JW, Monheit AC, Beauregard KR. The Medical Expenditure Panel Survey: a national health information resource. Inquiry. 1997;33:373-389.
27. Cohen JW. Design and Methods of the Medical Expenditure Panel Survey Household Component. Rockville, MD: Agency for Health Care Policy; 1997.
28. Moeller JF, Stagnitti MN, Horan E, et al. Outpatient Prescription Drugs: Data Collection and Editing in the 1996 Medical Expenditure Panel Survey. Rockville, MD: Agency for Healthcare Research and Quality; 2001. Pub. No. 01-0002.
29. U.S. Census Bureau. Summary File data, 2000. Washington, DC: U.S. Census Bureau; 2001.
30. Auchincloss AH, Van Nostrand JF, Ronsaville D. Access to health care for older persons in the United States: personal, structural, and neighborhood characteristics. J Aging Health. 2001;13:329-354.
31. Bird HR, Andrews H, Schwab-Stone M, et al. Global measures of impairment for epidemiologic and clinical use with children and adolescents. Int J Methods Psychiatr Res. 1996;6:295-307.
32. Bird HR, Shaffer D, Fisher P, et al. The Columbia Impairment Scale (CIS): pilot findings on a measure of global impairment for children and adolescents. Int J Methods Psychiatr Res. 1993;3:167-176.
33. Bussing R, Schoenberg N, Perwien A. Knowledge and information about ADHD: evidence of cultural differences among African-American and White parents. Soc Sci Med. 1998;46:919-928.
34. Bussing R, Schoenberg NE, Rogers KM, et al. Explanatory models of ADHD: do they differ by ethnicity, child gender or treatment status? J Emot Behav Disord. 1998;6:233-241.
35. Bussing R, Gary FA, Mills TL, et al. Parental explanatory models of ADHD. Gender and cultural variations. Soc Psychiatry Psychiatr Epidemiol. 2003;38:563-575.
36. Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000;105:1158-1170.